DRG Market Assessment reports

Treatment of chronic spontaneous and chronic inducible urticaria is dominated by oral medications—both approved (e.g., first- and second-generation antihistamines) and off-label (e.g., DMARDs,…

Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the…

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…

With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of mucopolysaccharidoses (MPS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States,…

Since the approval of immune checkpoint inhibitors, the treatment of bladder cancer has been transformed. Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now options in earlier…

Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…